Skip to main content

Sheng Mai San protects H9C2 cells against hyperglycemia-induced apoptosis



Sheng Mai San (SMS) has been proven to exhibit cardio-protective effects. This study aimed to explore the molecular mechanisms of SMS on hyperglycaemia (HG)-induced apoptosis in H9C2 cells.


HG-induced H9C2 cells were established as the experimental model, and then treated with SMS at 25, 50, and 100 μg/mL. H9C2 cell viability and apoptosis were quantified using MTT and Annexin V-FITC assays, respectively. Furthermore, Bcl-2/Bax signalling pathway protein expression and Fas and FasL gene expression levels were quantified using western blotting and RT-PCR, respectively.


SMS treatments at 25, 50, 100 μg/mL significantly improved H9C2 cell viability and inhibited H9C2 cell apoptosis (p < 0.05). Compared to the HG group, SMS treatment at 25, 50, and 100 μg/mL significantly downregulated p53 and Bax expression and upregulated Bcl-2 expression (p < 0.05). Moreover, SMS treatment at 100 μg/mL significantly downregulated Fas and FasL expression level (p < 0.05) when compared to the HG group.


SMS protects H9C2 cells from HG-induced apoptosis probably by downregulating p53 expression and upregulating the Bcl-2/Bax ratio. It may also be associated with the inhibition of the Fas/FasL signalling pathway.

Peer Review reports


Diabetes mellitus (DM) is on the verge of becoming a global epidemic. According to a report by the International Diabetes Federation, DM currently affects nearly 4250 million people [1]. In China, DM affects 10.9% of the population, which accounts for about a third of the diabetic patients worldwide [2]. Cardiovascular complications are the primary cause of disability and death due to DM. The medical expenses associated with diabetic macrovascular complications accounts for 80% of the total amount, making DM a huge economic burden on the society [3]. Therefore, it is imperative to prevent or delay the onset and development of diabetic cardiovascular complications. Diabetic cardiomyopathy (DCM), a major complication associated with DM, is defined as the dysfunction of the left ventricle in diabetic patients, in the absence of coronary artery disease or hypertension [4, 5]. It is initially characterized by left ventricular diastolic dysfunction and interstitial fibrosis, followed by systolic dysfunction and ejection fraction, and eventually resulting in heart failure [5,6,7]. Notably, cardiomyocyte apoptosis plays an important role in the pathophysiological mechanisms associated with DCM. There are two major mechanisms regulating this apoptosis. The first mechanism involves an intrinsic pathway, also called ‘the mitochondrion pathway’, such as the one regulating the B cell lymphoma/leukemia-2 (Bcl-2) protein family. The other apoptosis mechanism occurs via signaling by death receptor members, such as factor associated suicide (Fas)/factor associated suicide ligand (Fas-L) [8]. Hyperglyceamia activates the protein 53 (p53), and the renin-angiotensin system (RAS), resulting in the production of angiotensin II (Ang II), which leads to a decrease in Bcl-2 expression and an increase in Bcl-2 associated X protein (Bax) expression and, thus, plays an important role in promoting apoptosis [9, 10]. Bcl-2 and Bax are key proteins that regulate apoptosis [11]. P53 is a tumour suppressor gene that induces apoptosis by blocking cellular DNA damage repair [12]. Fas/FasL signaling is also crucial for cardiomyocyte apoptosis as it mainly regulates caspase-3 [13]. Currently, Western medicine is mainly focused on glycaemic control and treatment or prevention of risk factors associated with cardiovascular disease; however, these approaches do not fundamentally solve the problem of cardiac dysfunction [4, 14, 15].

Sheng Mai San (SMS) is a classical traditional Chinese formula containing the root of Radix Ginseng (Ren Shen), rootstock of Radix Ophiopogonis (Mai Dong), and dry ripe fruit of Fructus Schisandrae (Wu Wei Zi), which is recorded in the Yi Xue Qi Yuan, compiled by Yuan-su Zhang. It was mainly used for treating heart failure, myocardial ischemia, coronary heart disease, arrhythmia, myocarditis, and sick sinus syndrome [16,17,18]. We have earlier shown that SMS treatment alleviated myocardial damage and inhibited myocardial fibrosis in diabetic rats. SMS has also been proven to suppress cardiomyocyte apoptosis; however, its upstream mechanism is still unclear [19, 20]. Therefore, in this study, our aim was to explore the mechanisms underlying SMS activity with respect to cardiomyocyte apoptosis and provide new scientific evidence in favor of using traditional Chinese medicine to prevent DCM related damage.


Sheng Mai San standardisation

SMS was provided by Kangmei Pharmaceutical Co., Ltd. after adequate quality measurement. All the herbs were taken from the same batch. Decoctions were made at Guang’ anmen Hospital, China Academy of Chinese Medical Sciences, according to standard operating procedures. The major compounds in SMS were identified using high-performance liquid chromatography (HPLC; Waters 2695 HPLC system; Waters, CA, USA). A Luna® Omega Polar C18 analytical column (250 × 4.6 mm, 3.0 μm; Phenomenex, CA, USA) with a mobile phase that contained acetonitrile (A) and − 0.2% phosphoric acid acid in water (B) was used. The mobile phase gradient elution was programmed as follows: The mobile phase gradient elution was programmed as follows: 27% A (0–10 min), 27–38% A (10–12 min), 38% A (12–20 min), and 38–90% A (20–60 min); 73% B (0–10 min), 73–62% B (10–12 min), 62% B (12–20 min), and 62–10% B (20–60 min). The column temperature was maintained at 35 C, the flow rate was set at 0.5 mL/min, and a detection wavelength of 203 nm was used. SMS was dissolved in double distilled water containing 0.05% dimethylsulfoxide (DMSO). The solution was centrifuged, filtered and disinfected using a syringe filter (specification: 13 mm nylon filter, 0.45 μm,100 pcs/pack), and preserved at − 20 C for further experimentation [21].

Cell culture and drug treatment

Rat embryonic cardiomyoblast-derived H9C2 cells were obtained from the Cell Culture Center of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China). The cells were starved in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS and 1% penicillin/ streptomycin and cultured in a humidified atmosphere containing 5% CO2 at 37 °C for 24 h till they reached 60–70% confluency. H9C2 cells were then cultured in different sets for 24 h in DMEM containing a) 5.5 mM normal glucose (N), b) 30 mM D-glucose (H), c) 30 mM D-glucose with 25 μg/mL of SMS (25), d) 30 mM D-glucose with 50 μg/mL of SMS (50), and e) 30 mM D-glucose with 100 μg/mL of SMS (100). The requisite glucose concentration for inducing HG was determined based on a previously published study [22].

Cell viability analysis

H9C2 cell viability was detected via the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay, for which the cells were maintained for 24 h. The cells were treated with SMS, following with, they were incubated with MTT solution (0.5 mg/mL) for 4 h at 37 °C. The supernatant was discarded, 110 μL of 0.05% DMSO was added to each well in a 96-well plate, and the cells were incubated for 10 min. Absorbance (OD value) was measured using a microplate reader at a wavelength of 490 nm. Percentage of reduced MTT was considered to represent the decrease in H9C2 cell viability.

Cell apoptosis assay

H9C2 cell apoptosis was detected via Annexin-V fluorescein isothiocyanate/ propidium iodide (Annexin V-FITC/PI) staining. For this procedure, H9C2 cells were harvested using 0.05% trypsin, washed twice with cold phosphate buffered saline (PBS) (4 °C), and resuspended in 500 μg/mL of binding buffer at a concentration of 1 × 105 cells/mL. The cells were then incubated with Annexin V-FITC (5 μg/mL) and PI (5 μg/mL) in the dark for 15 mins at room temperature.

Cell-cycle analysis

H9C2 cells were cultured in DMEM for 24 h and then seeded at 4 × 105 cells/well in a 6-well culture plate. SMS was added as described in the section “Cell culture and drug treatment”. After treatment, the cells were collected and washed twice with PBS solution. RNase A solution (100 μL) was added, and the cells were incubated for 30 min at 37 °C, followed with 70% ethanol and then fixed at 4 °C for 2 h overnight. Subsequently, the cells were washed with PBS to remove the ethanol. Finally, cells were stained with 400 μL PI and incubated for 30 min at room temperature, and cell staining was measured using flow cytometry. The results were analyzed using the Cell Quest software. Percentage of cells in the G1 phase, the S phase, and the G2 phase was analyzed.

Western blotting

After SMS treatment, H9C2 cells were harvested, washed with cold phosphate-buffered saline (PBS), and incubated in radio immunoprecipitation assay (RIPA) buffer solusion (Solarbio, China) on ice. The total protein was then extracted from the cells and was quantified using a bicinchoninic acid (BCA) assay kit (Cwbiotech, China). Cell lysates were added to a loading buffer, separated using 12% sodium dodecyl sulfate-polyacrylaminde gel electrophoresis (SDS-PAGE), and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, USA). The membranes were blocked using Tris-Buffered Saline (TBS) blocking buffer and incubated with primary antibodies (CellSignaling Technology, USA) overnight at 4 °C. The dilution ratios used were as follows: rabbit monoclonal antibodies against Bcl-2 (1: 1000) and Bax (1: 1000), mouse monoclonal antibody against p53 (1: 1000). After washing the membranes thrice with Tris-Buffered Saline Tween-20 (TBST), they were incubated with HRP-conjugated secondary antibodies (Jackson ImmunoResearch, USA) for 1 h. The dilution ratios used were as follows: goat anti-rabbit antibody (1: 1500) and goat anti-mouse antibody (1: 1500). A chemiluminescence enhancing agent (Millipore, USA) was used to obtain the antigen-antibody complex band, and an image analyser (Bio-Rad, USA) was used to obtain band intensity via densitometric analysis. Protein expression was normalised to that of glyceraldehyde phosphatedehydrogenase (GAPDH) (Abcam, USA).

Real-time PCR

Total ribonucleic acid (RNA) was extracted using TRIzol (Invitrogen, USA). After determining concentration and purity, the total RNA was reverse transcribed into complementary DNA (cDNA) using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher, China) as per the manufacturer’s instructions. Real-time quantitative Polymerase Chain Reaction (PCR) was performed on a 2400 real-time PCR system using the SYBR® Green RT-PCR Reagents Kit (ABI, USA) to amplify the Fas, Fas-L and GAPDH genes. The Fas, Fas-L and GAPDH primer sequences used for amplification are shown in Table 1. Gene expression was normalized to that of GAPDH (Abcam, USA). Results were analyzed using the 2-CT method, and fold change, as compared to control, was determined.

Table 1 Primers sequences used for real-time quantitative PCR

Statistical analysis

Each experiment was performed at least three times. The values were expressed as mean ± standard deviation (SD). Data were evaluated using one-way analysis of variance (ANOVA), the post-hoc Test (Bonferroni and Tukey methods) was performed following ANOVA. SPSS version 20.0 (IBM Corp., Armonk, NY, USA) was used for the analyses. Values of p < 0.05 was considered to be statistically significant.


HPLC analysis of SMS

In order to standardise the chemical composition of the herbal medicine, we performed high performance liquid chromatography (HPLC) fingerprint analysis. Figure 1 shows a typical HPLC fingerprint of SMS, in which the major peaks were identified by comparing both the retention times of both SMS and the reference standards. Notably, 6 compounds in SMS, viz. 1) ginsenoside Re, 2) ginsenoside Rg1, 3) ginsenoside Rb1, 4) schisandrin, 5) ophiopogonin D, and 6) ruscogenin were properly identified.

Fig. 1

Chemical standardization of SMS (a) and its standard compounds (b) by high performance liquid chromatography (HPLC) fingerprint analysis (203 nm). In the HPLC fingerprint at an absorbance of 203 nm, the peaks corresponding to ginsenoside Re (1); ginsenoside Rg1 (2); ginsenoside Rb1 (3); schisandrin (4); ophiopogonin D (5); ruscogenin (6)

SMS increases cell viability within a certain dosage range

Hyperglycemia-induced H9C2 cells were treated with different concentrations of SMS for 24 h. The results revealed that H9C2 cell viability gradually increased (p < 0.05) with an increase in SMS concentrations. H9C2 cell viability was also observed to peak in the 100 μg/mL SMS group. For SMS concentrations reached above 200 μg/mL, H9C2 cell viability was observed to decline (p < 0.05; Fig. 2a). Although HG significantly reduced H9C2 cell viability compared to the NG group (46.7% ± 5.4% versus 76.2% ± 4.9%, p < 0.05), it appeared to be restored following an SMS pre-treatment. Compared with the HG group, SMS significantly increased H9C2 cell viability to 57.2% ± 5.7, 64.5% ± 6.2, and 76.2% ± 4.9% at concentrations of 25, 50, and 100 μg/mL (p < 0.05), respectively. Treatment with 100 μg/mL SMS significantly upregulated H9C2 cell viability compared with 25 μg/mL and 50 μg/mL SMS (p < 0.05), demonstrating a dose-dependent response (p < 0.05; Fig. 2b).

Fig. 2

Effects of SMS on the H9C2 cell viability. a H9C2 cells were treated with different concentrations of SMS under normal glucose environment for 24 h. (p < 0.05 vs. control cells). b SMS increases H9C2 cell viability exposed to HG (n = 3 in each group). (*p < 0.05: vs. NG group; p < 0.05: vs. HG group)

SMS protects H9C2 cells from HG-induced apoptosis

Hyperglycemia significantly increased the incidence of apoptosis in H9C2 cells. As shown in Fig. 3 a and b, the percentage of apoptotic cells markedly increased in the HG group compared to the NG group (58.5% ± 1.29% versus 4.16% ± 0.64%, p < 0.05). However, compared with the HG group, SMS attenuated HG-induced apoptosis, and apoptotic cells markedly decreased to 10.14% ± 0.77, 7.78% ± 1.05, and 4.80% ± 0.52% at concentrations of 25, 50 and 100 μg/mL (p < 0.05), respectively. The proportion of apoptotic cells in 25, 50, and 100 μg/mL SMS-pretreated groups decreased with increasing concentration of SMS, which indicated to be significantly difference (p < 0.05) (Fig. 3).

Fig. 3

Effect of SMS on the H9C2 cell apoptosis exposed to HG. a The percentage of apoptotic cells in each group. b Cells were detected with a flow cytometer

SMS affects the retention of the cell cycle in the H9C2 cells

To explore whether SMS-inhibited apoptosis was associated with cell cycle arrest, we detected the cell cycle distribution of H9C2 cells using flow cytometry to analyze cellular DNA content. As shown in Fig. 4, HG significantly reduced the percentage of H9C2 cells in the G1 phase compared with that in the NG group (43.77% ± 4.40% versus 62.58% ± 1.26%, p < 0.05). There was a marked increase in the percentage of cells in the G1 phase in H9C2 cells treated with 100 μg/mL of SMS for 24 h versus that in the HG group (51.78% ± 0.24% versus 43.77% ± 4.40%, p < 0.05), however, no significant difference existed between 25 and 50 μg/mL SMS-pretreated groups and HG group (51.78% ± 0.24% versus 43.77% ± 4.40, 50.76% ± 0.61% versus 43.77% ± 4.40%, respectively, for group 25 and 50, p > 0.05). Compared with the NG group, the percentage of H9C2 cells in the S phase significantly increased in the HG group (40.15% ± 3.13% versus 25.88% ± 0.30%, p < 0.05), whereas the percentage of cells in the S phase significantly decreased in H9C2 cells treated with 100 μg/mL and 50 μg/mL of SMS compared with that in the HG group (32.65% ± 0.52% versus 40.15% ± 3.13 and 33.71% ± 0.05% versus 40.15% ± 3.13%, respectively for group 100 and 50, p < 0.05). In addition, HG significantly increased the percentage of H9C2 cells in the G2 phase compared with that in the NG group (16.08% ± 1.26% versus 11.55% ± 1.56%, p < 0.05), but SMS-pretreated groups failed to significantly decrease the percentage of H9C2 cells compared with HG group (p > 0.05).

Fig. 4

Effect of SMS on the cell cycle in H9C2 cells. a The cell cycle of each group in H9C2 cells. b Distribution of cell cycle for H9C2 cells after treated with various concentrations of SMS for 24 h. (*p < 0.05: vs. NG group; p < 0.05: vs. HG group)

SMS inhibits HG-induced apoptosis by decreasing p53 and Bax expression and increasing Bcl-2 expression

To determine the mechanisms underlying the SMS-mediated inhibition of HG-induced apoptosis, we examined apoptosis-related protein expression levels via western blotting. As presented in Fig. 5, Bax expression levels were markedly increased in the HG group compared to those in the NG group (1302.0 ± 106.1 versus 90.7 ± 13.9, p < 0.05). Bax expression level was decreased in a dose-dependent manner in the SMS pretreatment group relative to the H2O2 group to 1065.1 ± 44.1, 962.8 ± 67.3, and 479.9 ± 39.4 at concentrations of 25, 50 and 100 μg/mL (p < 0.05), and treatment with 100 μg/mL SMS significantly decreased Bax compared with 25 μg/mL and 50 μg/mL SMS (p < 0.05). Bcl-2 expression was also markedly decreased in the HG group when compared to that in the NG group (296.8 ± 22.1 versus 3668.0 ± 154.3, p < 0.05), and SMS treatment at 50 and 100 μg/mL for 24 h markedly increased Bcl-2 expression compared with HG group (1628.5 ± 64.6 versus 296.8 ± 22.1 and 2126.1 ± 100.9 versus 296.8 ± 22.1, respectively, p < 0.05). P53 expression levels were markedly increased in the HG group (2792.3 ± 70.2 versus 520.4 ± 41.8, p < 0.05). However, p53 expression levels was significantly reduced by SMS pretreatment in a concentration-dependent manner (2259.1 ± 89.2, 1126.5 ± 53.2, 520.4 ± 41.8, respectively, p < 0.05 for group 25, 50 and 100). Therefore, SMS inhibited HG-induced apoptosis probably by downregulating Bax expression and p53 expression and upregulating Bcl-2 expression.

Fig. 5

Western blot and quantitative measurement for p53, Bax and Bcl-2 protein expressions in H9C2 cells. a Western blot. b Quantitative measurement. (*p < 0.05: vs. NG group; p < 0.05: vs. HG group)

SMS downregulates Fas and FasL mRNA expression levels in H9C2 cells

Fas and FasL gene expression levels were examined in order to further clarify the molecular mechanism of the SMS-mediated inhibition of apoptosis. RT-PCR results in Fig. 6a showed that Fas expression was significantly upregulated in the HG group (1.21 ± 0.19 versus 1.00 ± 0.25, p < 0.05), and this expression was dramatically reversed by SMS treatment at a concentration of 100 μg/mL for 24 h (0.82 ± 0.12 versus 1.21 ± 0.19, p < 0.05). However, no obvious difference in Fas expression was observed between the groups treated with SMS at 25 μg/mL and 50 μg/mL) and the HG group (p > 0.05). RT-PCR results in Fig. 6b showed that FasL expression was significantly upregulated in the HG group (1.27 ± 0.12 versus 1.00 ± 0.09, p < 0.05) and this expression was dramatically reversed by treatment with SMS at 100 μg/mL for 24 h (0.86 ± 0.09 versus 1.27 ± 0.12, p < 0.05). However, no significant difference in FasL expression was observed between the groups treated with SMS at 25 μg/mL and 50 μg/mL and the HG group (p > 0.05).

Fig. 6

Real-time PCR analysis for Fas and FasLgene expression in H9C2 cells. a RT-PCR analysis for Fas. b RT-PCR analysis for FasL. (*p < 0.05: vs. NG group; p < 0.05: vs. HG group)


Sheng Mai San (SMS), an aqueous amalgamation of the extracts of Radix Ginseng (Ren Shen), Radix Ophiopogonis (Mai Dong), and Fructus Schisandrae (Wu Wei Zi), is a common traditional Chinese medicine (TCM) that is used to treat cardiovascular diseases [16,17,18,19, 23]. In the HPLC analysis, ginsenoside Re, ginsenoside Rg1, ginsenoside Rb1, schisandrin, ophiopogonin D, and ruscogenin were identified. Ginsenoside is an important active ingredient in Radix Ginseng (Ren Shen). Ginsenoside Re inhibits cardiomyocyte apoptosis by inhibiting expression of pro-apoptotic Bax gene and raising the ratio of Bcl-2/Bax [24]. Ginsenoside Rg1 inhibits the Jun N-terminal Kinase (JNK) pathway in H9c2 cells to protect against oxidative stress, which is regarded as a major cause of H9c2 cardiomyocyte apoptosis [25]. Ginsenoside Rb1 exerts significant and anti-diabetic effects by regulating the effects of glycolipid metabolism and improving insulin and leptin sensitivities [26]. Ginsenoside Rb1 protects HG- cardiomyocyte apoptosis, at least in part via the inhibition of caspase-3 activity and the Bax/Bcl-2 ratio [27]. Schisandrin B may attenuate the inflammatory response, oxidative stress and apoptosis in TSCI rats by inhibiting the p53 signaling pathway in rats [28]. Ophiopogonin D may protect cardiomyocytes against injury through suppressing endoplasmic reticulum stress [29]. The therapeutic effects of ruscogenin was determined in the Sheng-Mai-San. Although this is a traditional compound preparation, its constitution of bioactive components has been initially determined, including ginsenoside Rb1, ruscogenin and schisandrin. It exerts significant cardioprotection against myocardial ischemia injury by decreasing myocardium infarct size and regulating myocardial enzymes indexes [17]. In this study, the effect of SMS in the prevention and treatment of DCM was investigated. We showed that SMS treatment could inhibit HG-induced apoptosis and affect the retention of the H9C2 cell cycle. Notably, DM is associated with cardiac structural and functional changes, which lead to DCM.

The Bcl-2 protein family is the most widely studied and the most important apoptosis-regulating factor that regulates apoptosis mainly by maintaining the dynamic balance between pro-apoptotic and anti-apoptotic proteins [11]. P53 as a tumour suppressor gene that activates its downstream targets in a sequential manner in order to induce apoptosis and plays an important role in the prevention of cardiac fibrosis and heart failure [30, 31]. A previous study indicated that p53 directly activated Bax and suppressed Bcl-2 in order to permeabilize mitochondria and engage the apoptotic mechanism [32]. Our study investigated the expression levels of p53, Bax and Bcl-2 in HG-induced H9C2 cells. While p53 and Bax expression was perceptibly increased, Bcl-2 protein expression was notably decreased. This imbalance in protein expression was consistent with increased cardiomyocyte apoptosis. However, after SMS treatment, p53 and Bax expression was significantly downregulated and Bcl-2 expression was significantly upregulated when compared to the HG group.

To explore the molecular mechanisms underlying the SMS-mediated inhibition of HG-induced apoptosis in H9C2 cells, this study also investigated Fas and FasL expression. The Fas/FasL signaling pathway can directly trigger cardiomyocyte apoptosis and has been reported in studies related to cardiovascular diseases [33]. Fas is a transmembrane glycoprotein that is the most important death receptor for activation-induced cell death. On the contrary, Fas ligand (FasL) is a kind of type 2 transmembrane glycoprotein. Notably, the Fas/FasL combination causes an accumulation of intracellular ‘death-inducing signalling complexes’ that provide the necessary factors for Fas-mediated apoptosis [34]. This study indicated that Fas and FasL mRNA expression levels are significantly upregulated in the HG group; however, they are downregulated upon treatment with increasing concentrations of SMS, with the most significant downregulation observed at 100 μg/mL SMS. This suggests abatement in the apoptotic process by SMS.

The study has a few limitations that need to be addressed through further studies. First, the upstream mechanisms associated with the protective effect of SMS in cardiomyocyte apoptosis still need to be elucidated. Second, further experiments using a primary culture of neonatal rat cardiomyocytes are also needed to strengthen the conclusion that SMS inhibits apoptosis.


In conclusion, SMS protected H9C2 cells from HG-induced damage and improved their viability by suppressing apoptosis. The protection offered by SMS against cardiomyocyte apoptosis was mediated by the downregulation of P53 expression and regulation of the Bcl-2/Bax signaling pathway. SMS at a 100 μg/mL concentration also downregulated Fas and FasL mRNA expression level in HG-induced H9C2 cells. We can, thus, surmise that SMS prevents and treats damage caused by DCM by regulating apoptosis-related mechanisms.

Availability of data and materials

The datasets used or analyzed during the study are available from the corresponding author on reasonable request.


Ang II:

Angiotensin II

Annexin V-FITC/PI:

Annexin-V fluorescein isothiocyanate/propidium iodide


One-way analysis of variance


Bcl-2 associated X protein


Bicinchoninic acid


B cell lymphoma/leukemia-2


complementary DNA


Diabetic cardiomyopathy


Diabetes mellitus


Dulbecco’s Modified Eagle Medium




Factor associated suicide


Factor associated suicide ligand


Glyceraldehyde phosphatedehydrogenase




High-performance liquid chromatography


Jun N-terminal Kinase




Normal glucose


Protein 53


Phosphate buffered saline


Polyvinylidene fluoride


Renin-angiotensin system


Radio immunoprecipitation assay


Ribonucleic acid


Standard deviation


Sodium dodecyl sulfate-polyacrylaminde gel electrophoresis


Tris-buffered saline


Tris-Buffered Saline Tween-20


Traditional Chinese medicine


  1. 1.

    International Diabetes Federation, IDF Diabetes Altas Globally, International Diabetes Federation, 8th edition. 2017, p. 9.

  2. 2.

    Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, Li Y, Zhao Z, Qin X, Jin D, Zhou M, Tang X, Hu Y, Wang L. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;317(24):2515–23.

    Article  Google Scholar 

  3. 3.

    Sun L, Wang GX. Interpretation of cardiovascular events in the latest Sino-American diabetes diagnosis and treatment guidelines. Zhong Guo Yi Xue Qian Yan Za Zhi. 2015;7(3):10–5.

    Google Scholar 

  4. 4.

    Tate M, Grieve DJ, Ritchie RH. Are targeted therapies for diabetic cardiomyopathy on the horizon? Clin Sci (Lond). 2017;131(10):897–915.

    CAS  Article  Google Scholar 

  5. 5.

    Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57(4):660–71.

    CAS  Article  Google Scholar 

  6. 6.

    Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–38.

    CAS  Article  Google Scholar 

  7. 7.

    Ma ZG, Yuan YP, Xu SC, Wei WY, Xu CR, Zhang X, Wu QQ, Liao HH, Ni J, Tang QZ. CTRP3 attenuates cardiac dysfunction, inflammation, oxidative stress and cell death in diabetic cardiomyopathy in rats. Diabetologia. 2017;60(6):1126–37.

    CAS  Article  Google Scholar 

  8. 8.

    Sun C, Liu H, Guo J, Yu Y, Yang D, He F, Du Z. MicroRNA-98 negatively regulates myocardial infarction-induced apoptosis by down-regulating Fas and caspase-3. Sci Rep. 2017;7(1):7460.

    Article  Google Scholar 

  9. 9.

    Ikeda S, Hamada M, Qu P, Hiasa G, Hashida H, Shigematsu Y, Hiwada K. Relationship between cardiomyocyte cell death and cardiac function during hypertensive cardiac remodeling in Dahl rats. Clin Sci. 2002;102(3):329–35.

    Article  Google Scholar 

  10. 10.

    Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, Anversa P, Kajstura J. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes. 2001;50(10):2363–75.

    CAS  Article  Google Scholar 

  11. 11.

    Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63.

    CAS  Article  Google Scholar 

  12. 12.

    Chang H, Li C, Huo K, Wang Q, Lu L, Zhang Q, Wang Y, Wang W. Luteolin prevents H2O2-induced apoptosis in H9C2 cells through modulating Akt-P53/Mdm2 signaling pathway. Biomed Res Int. 2016;2016:5125836.

    PubMed  PubMed Central  Google Scholar 

  13. 13.

    Wang LL, Li M, Li XL. Effect of Fas/FasL on diabetic cardiomyopathy. Zhong Guo Dang Dai Yi Yao. 2015;22(18):14–6.

    Google Scholar 

  14. 14.

    Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycemic drug therapy. Lancet. 2015;385(9982):2107–17.

    CAS  Article  Google Scholar 

  15. 15.

    Teupe C, Rosak C. Diabetic cardiomyopathy and diastolic heart failure--difficulties with relaxation. Diabetes Res Clin Pract. 2012;97(2):185–94.

    CAS  Article  Google Scholar 

  16. 16.

    Zhou Q, Qin WZ, Liu SB, Kwong JS, Zhou J, Chen J. Shengmai (a traditional Chinese herbal medicine) for heart failure. Cochrane Database Syst Rev. 2014;4:CD005052.

    Google Scholar 

  17. 17.

    Li F, Fan XX, Chu C, Zhang Y, Kou JP, Yu BY. A strategy for optimizing the combination of active components based on Chinese medicinal formula sheng-Mai-san for myocardial ischemia. Cell Physiol Biochem. 2018;45(4):1455–71.

    CAS  Article  Google Scholar 

  18. 18.

    Zhang YC, Lu BJ, Zhao MH, Rong YZ, Chen RM. Effect of Shengmai injection on vascular endothelial and heart functions in patients with coronary heart disease complicated with diabetes mellitus. Chin J Integr Med. 2008;14(4):281–5.

    Article  Google Scholar 

  19. 19.

    Ni Q, Wang J, Li EQ, Zhao AB, Yu B, Wang M, Huang CR. Study on the protective effect of shengmai san (see text) on the myocardium in the type 2 diabetic cardiomyopathy model rat. J Tradit Chin Med. 2011;31(3):209–19.

    Article  Google Scholar 

  20. 20.

    Ni Q, Wang J, Li EQ, Zhao AB, Yu B, Wang M, Huang CR. Study on the protective effect of the mixture of Shengmai powder and Danshen decoction on the myocardium of diabetic cardiomyopathy in the rat model. Chin J Integr Med. 2011;17(2):116–25.

    Article  Google Scholar 

  21. 21.

    Lin S, Lin JM, Zhang L, Chen DX, Xiao F, Chen HW, Chen YQ, Zhu YL, Chu JF, Peng J. Shexiang Tongxin dropping pill protects against Na2S2O4-induced hypoxia-reoxygenation injury in H9c2 cells. Chin J Integr Med. 2019;25(6):439-45.

  22. 22.

    Xu K, Liu XF, Ke ZQ, Yao Q, Guo S, Liu C. Resveratrol modulates apoptosis and autophagy induced by high glucose and palmitate in cardiac cells. Cell Physiol Biochem. 2018;46(5):2031–40.

    CAS  Article  Google Scholar 

  23. 23.

    Tian J, Zhao Y, Liu Y, Liu Y, Chen K, Lyu S. Roles and mechanisms of herbal medicine for diabetic cardiomyopathy: current status and perspective. Oxidative Med Cell Longev. 2017;2017:8214541.

    Google Scholar 

  24. 24.

    Liu Z, Li Z, Liu X. Effect of ginsenoside re on cardiomyocyte apoptosis and expression of Bcl-2/Bax gene after ischemia and reperfusion in rats. J Huazhong Univ Sci Technolog Med Sci. 2002;22(4):305–9.

    Article  Google Scholar 

  25. 25.

    Li Q, Xiang Y, Chen Y, Tang Y, Zhang Y. Ginsenoside Rg1 protects Cardiomyocytes against hypoxia/Reoxygenation injury via activation of Nrf2/HO-1 signaling and inhibition of JNK. Cell Physiol Biochem. 2017;44(1):21–37.

    Article  Google Scholar 

  26. 26.

    Zhou P, Xie W, He S, Sun Y, Meng X, Sun G. Ginsenoside Rb1 as an anti-diabetic agent and its underlying mechanism analysis. Cells. 2019;8(3).

    Article  Google Scholar 

  27. 27.

    Zhao D, Zhang M, Yuan H, Meng C, Zhang B, Wu H. Ginsenoside Rb1 protects against spinal cord ischemia-reperfusion injury in rats by downregulating the Bax/Bcl-2 ratio and caspase-3 and p-Ask-1 levels. Exp Mol Pathol. 2018;105(3):229–35.

    CAS  Article  Google Scholar 

  28. 28.

    Xin DQ, Hu ZM, Huo HJ, Yang XJ, Han D, Xing WH, Zhao Y, Qiu QH. Schisandrin B attenuates the inflammatory response, oxidative stress and apoptosis induced by traumatic spinal cord injury via inhibition of p53 signaling in adult rats. Mol Med Rep. 2017;16(1):533–8.

    CAS  Article  Google Scholar 

  29. 29.

    Wang J, Wang NN, Ge YX, Tan HL, Ma ZCM, Wang YG, Gao Y. Ophiopogonin D protects cardiomyocytes against ophiopogonin D'-induced injury through suppressing endoplasmic reticulum stress. Zhongguo Zhong Yao Za Zhi. 2019;44(9):1876–81.

    PubMed  Google Scholar 

  30. 30.

    Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun. 2005;331(3):851–8.

    CAS  Article  Google Scholar 

  31. 31.

    Gogiraju R, Xu X, Bochenek ML, Steinbrecher JH, Lehnart SE, Wenzel P, Kessel M, Zeisberg EM, Dobbelstein M, Schäfer K. Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice. J Am Heart Assoc. 2015;4(2).

  32. 32.

    Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303(5660):1010.

    CAS  Article  Google Scholar 

  33. 33.

    Liu XM, Yang ZM, Liu XK. Fas/FasL induces myocardial cell apoptosis in myocardial ischemia-reperfusion rat model. Eur Rev Med Pharmacol Sci. 2017;21(12):2913–8.

    PubMed  Google Scholar 

  34. 34.

    Wang S, Tang Y, Cui H, Zhao X, Luo X, Pan W, Huang X, Shen N. Let-7/miR-98 regulates Fas and Fas-mediated apoptosis. Genes Immun. 2011;12(2):149–54.

    Article  Google Scholar 

Download references


Not applicable.


This study is supported by a grant from the National Natural Science Foundation of China (Grant No. 81173258). The authors thank National Natural Science Foundation of China for its assistance in the design of the study, and its scheme provides main study methods and indicators of mechanism.

Author information




NQ conceived the study, and participated in its design. PB, SLW and DLJ participated in the cell viability and apoptosis analysis, Western blot and RT-PCR study. LYC and ZMZ performed the statistical analysis. PB wrote the initial manuscript, NQ helped to revise it critically. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Qing Ni.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pang, B., Shi, L., Du, L. et al. Sheng Mai San protects H9C2 cells against hyperglycemia-induced apoptosis. BMC Complement Altern Med 19, 309 (2019).

Download citation


  • Sheng Mai San
  • H9C2 cells
  • Apoptosis
  • Bcl-2/Bax signaling way
  • Fas/FasL signaling way